Foundayo's weekly prescriptions reach about 7,000, a modest start

Eli Lilly's oral obesity drug Foundayo was prescribed 7,335 times in the U.S. during its fourth week on the market, up from 5,612 the week before, according to data cited by analysts and reported by Reuters ^[1][2]. The pill's rollout is being compared closely with Novo Nordisk's Wegovy pill, which launched in January and had a head start in the oral weight-loss market ^[1][2].

Foundayo was approved on April 1, with prescriptions accepted immediately through LillyDirect, shipping starting April 6, and broader availability at retail pharmacies and telehealth providers beginning April 9 ^[1][2]. By comparison, Wegovy's pill was prescribed more than 18,000 times in its first full week and had climbed to more than 134,000 weekly prescriptions by its 16th week ^[2].

Lilly executives said last week that Foundayo now has more than 8,000 prescribers, a third of whom had not previously written an oral GLP-1 prescription, and that more than 20,000 patients have been treated with the drug ^[1][2]. More than 12 major telehealth firms are offering Foundayo, accounting for about 35% of launch volume ^[1].

RBC Capital Markets analyst Trung Huynh said Foundayo would need roughly 22,000 prescriptions a week to meet consensus expectations of $160 million in second-quarter sales ^[1]. Looking further out, Huynh said the drug would need to reach more than 90,000 weekly prescriptions by its 12th week to stay on track for average annual sales estimates of about $1.4 billion ^[2]. Some analysts caution that the tracking data, based on IQVIA figures covering retail prescriptions plus samples of telehealth, LillyDirect, and mail-order activity, may undercount actual use because of gaps in telehealth reporting, which could make weekly numbers fluctuate ^[1][2]. Huynh noted that given roughly 20,000 patients already treated as of last week's earnings call, "there is a capture rate issue with the data" ^[2]. Even so, Huynh said some investors are "beginning to see... past initial weekly script tracking metrics as the barometer" for the drug's longer-term potential, betting instead on how much oral pills could expand the overall weight-loss drug market ^[1].

Why it matters for patients

For patients weighing an oral option instead of an injectable GLP-1 drug, the early numbers give a sense of how quickly a new alternative is becoming available through doctors and telehealth services, though they say nothing about how well the drug works or its safety profile compared with existing options. The fact that a third of Foundayo's prescribers are new to oral GLP-1 drugs suggests some doctors who had not offered a pill option before are now willing to prescribe one ^[1][2]. Slower-than-expected uptake could also affect how quickly insurers and pharmacies stock and cover the drug, and how much competition affects pricing across the oral weight-loss category over time, though the sources do not address insurance coverage or price changes directly. It is not yet known from these sources whether prescription growth will accelerate enough to meet analysts' benchmarks, or how patients using the drug are faring beyond the raw prescription counts.

What happens next

Analysts say it will take about 8 to 12 weeks from launch to get a clearer picture of the drug's real commercial momentum, since early data may be distorted by reporting gaps ^[2]. That would put a more reliable read around late May to late June 2026. Huynh's benchmark of 90,000 weekly prescriptions by week 12, and the second-quarter sales consensus of $160 million, are the near-term markers analysts are watching for signs of whether Foundayo's growth is on pace ^[1][2].